Details
Stereochemistry | ACHIRAL |
Molecular Formula | Gd |
Molecular Weight | 157.25 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Gd]
InChI
InChIKey=UIWYJDYFSGRHKR-UHFFFAOYSA-N
InChI=1S/Gd
Molecular Formula | Gd |
Molecular Weight | 157.25 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7960618; https://www.ncbi.nlm.nih.gov/pubmed/?term=23435930; http://mnoncology.com/disease-drug-info/drug-dictionary/G/
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7960618; https://www.ncbi.nlm.nih.gov/pubmed/?term=23435930; http://mnoncology.com/disease-drug-info/drug-dictionary/G/
DOTAREM (Gadoterate Meglumine ) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associatedtissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Gadoterate Meglumine is a gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI.
CNS Activity
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdf
Curator's Comment: Gadoterate does not cross the intact blood-brain barrier and, therefore, does not enhance normal brain or lesions that have a normal blood-brain barrier, e.g. cysts, mature post-operative scars. However, disruption of the bloodbrain barrier or abnormal vascularity allows distribution of gadoterate in lesions such as neoplasms, abscesses, and infarcts.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7960618http://www.prnewswire.com/news-releases/fda-approves-dotarem-gadoterate-meglumine-first-macrocyclic-and-ionic-gadolinium-based-contrast-agent-in-usa-199354771.html
Curator's Comment: # Schering AG (now subsidiary of Bayer)
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P27169 Gene ID: 5444.0 Gene Symbol: PON1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/31179770 |
105.0 mM [Ki] | ||
Target ID: P52209 Gene ID: 5226.0 Gene Symbol: PGD Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20235752 |
73.0 mM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | DOTAREM Approved UseIndicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Launch Date1.36373758E12 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date1.30006083E12 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date1.30006083E12 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date1.30006083E12 |
PubMed
Title | Date | PubMed |
---|---|---|
Zinc allosterically modulates antagonist binding to cloned D1 and D2 dopamine receptors. | 1997 May |
|
Aluminum is a weak agonist for the calcium-sensing receptor. | 1999 May |
|
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel. | 2001 Feb 16 |
|
Inhibition of transiently expressed low- and high-voltage-activated calcium channels by trivalent metal cations. | 2002 Jun 1 |
|
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. | 2002 May 15 |
|
Gadolinium-containing contrast media for radiographic examinations: a position paper. | 2002 Oct |
|
A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. | 2004 May |
|
Gadolinium contrast may be risky in kidney disease. | 2007 Jun 30 |
|
Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. | 2008 Aug |
|
Use of gadolinium for carotid artery angiography and stenting in patients with renal insufficiency. | 2009 Dec |
|
Differential expression of TRPM2 and TRPV4 channels and their potential role in oxidative stress-induced cell death in organotypic hippocampal culture. | 2010 Mar |
|
Heavy metal cations permeate the TRPV6 epithelial cation channel. | 2011 Jan |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:29:52 UTC 2023
by
admin
on
Fri Dec 15 18:29:52 UTC 2023
|
Record UNII |
AU0V1LM3JT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C637
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
||
|
DSLD |
1412 (Number of products:27)
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1310171
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
PRIMARY | RxNorm | ||
|
33375
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
PRIMARY | |||
|
23982
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
PRIMARY | |||
|
Gadolinium
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
PRIMARY | |||
|
AU0V1LM3JT
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
PRIMARY | |||
|
231-162-2
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
PRIMARY | |||
|
7536
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
PRIMARY | |||
|
AU0V1LM3JT
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
PRIMARY | |||
|
m5626
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
PRIMARY | Merck Index | ||
|
100000091328
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
PRIMARY | |||
|
SUB25651
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
PRIMARY | |||
|
D005682
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
PRIMARY | |||
|
7440-54-2
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
PRIMARY | |||
|
C39765
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
PRIMARY | |||
|
DTXSID5037234
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
PRIMARY | |||
|
DB12091
Created by
admin on Fri Dec 15 18:29:52 UTC 2023 , Edited by admin on Fri Dec 15 18:29:52 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |